916479.fig.001a
(a)
916479.fig.001b
(b)
916479.fig.001c
(c)
916479.fig.001d
(d)
Figure 1: Survival after landmark of 18 months for all patients (a) and for those with NR, PR, or CR as best response at 18 months, with patients separated by early versus later treatment period. Note: longer survival among all patients treated recently but similar survival for patients with the same response status.